Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Ezetimibe is a prescription cholesterol absorption inhibitor. It is used alone or with other lipid-lowering medicines for selected primary hyperlipidemia, familial hypercholesterolemia, mixed hyperlipidemia, and homozygous familial sitosterolemia. Each tablet contains 10 mg.
read more about ezetimibe ...Ezetimibe acts at the brush border of the small intestine and inhibits the NPC1L1 sterol transporter. This decreases intestinal absorption of cholesterol and phytosterols and reduces delivery of intestinal cholesterol to the liver. The result is increased clearance of cholesterol from the blood.
Ezetimibe treats primary hyperlipidemia in adults and is used with a statin for heterozygous familial hypercholesterolemia from age 10. It is also used with other LDL-lowering therapy for homozygous familial hypercholesterolemia from age 10 and for homozygous familial sitosterolemia from age 9. Adult mixed hyperlipidemia can be treated with ezetimibe plus fenofibrate.
The recommended dose is 10 mg by mouth once daily with or without food. When a bile acid sequestrant is also used, ezetimibe is taken at least two hours before or at least four hours after the sequestrant. LDL cholesterol can be assessed as early as four weeks after treatment begins.
Serious concerns include liver enzyme elevations, myopathy, rhabdomyolysis, and hypersensitivity reactions such as anaphylaxis and angioedema. Muscle toxicity risk increases with selected statins or fibrates. Cyclosporine can increase exposure to ezetimibe, and cyclosporine concentrations are monitored when the medicines are used together.
Ezetimibe is a cholesterol absorption inhibitor that blocks intestinal uptake of cholesterol and phytosterols.
The recommended dose is 10 mg once daily with or without food.
Yes. Current labeling includes selected familial lipid disorders beginning at age 9 or 10 depending on the indication.
Yes. Myopathy and rhabdomyolysis have been reported, especially with other medicines that also increase muscle toxicity risk.
DailyMed - EZETIMIBE tablet. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6407d7f3-fd92-4c36-b561-f95ab7ebe055. Date Accessed September 30, 2026.
Ezetimibe. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK548095/. Date Accessed September 30, 2026.
Ezetimibe. MedlinePlus. https://medlineplus.gov/druginfo/meds/a603015.html. Date Accessed September 30, 2026.
Ezetimibe. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Ezetimibe. Date Accessed September 30, 2026.
Ezetimibe. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK532879/. Date Accessed September 30, 2026.